Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19José F. Varona, José Jimeno, María José Pontes et al.|Life Science Alliance|2022Cited by 52
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trialPablo Ryan, Estebán Martínez, José L Blanco et al.|The Lancet HIV|2025Cited by 22
Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical TrialRocío Montejano, Fernando Calle, María Velasco et al.|Clinical Infectious Diseases|2022Cited by 20
48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohortAlfonso Cabello, Miguel Górgolas, Juan Carlos López Bernardo de Quirós et al.|PLoS ONE|2022Cited by 20
Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015José Antonio Iribarren, Miguel Ángel von Wichmann, Rafael Rubio et al.|Enfermedades Infecciosas y Microbiología Clínica|2016Cited by 18